WallStreetZenWallStreetZen

NASDAQ: ABEO
Abeona Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ABEO

Based on 4 analysts offering 12 month price targets for Abeona Therapeutics Inc

Min Forecast
$15.00+165.96%
Avg Forecast
$18.75+232.45%
Max Forecast
$20.00+254.61%

Should I buy or sell ABEO stock?

Based on 4 analysts offering ratings for Abeona Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ABEO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ABEO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ABEO stock forecasts and price targets.

ABEO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-18
lockedlocked$00.00+00.00%2025-08-15
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-03-24

1 of 1

Forecast return on equity

Is ABEO forecast to generate an efficient return?

Company
34.8%
Industry
130.14%
Market
-52.51%
ABEO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABEO forecast to generate an efficient return on assets?

Company
23.12%
Industry
47.48%
ABEO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABEO earnings per share forecast

What is ABEO's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.30+22.33%
Avg 2 year Forecast
$0.13-87.74%
Avg 3 year Forecast
$1.16+9.43%
ABEO's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ABEO revenue forecast

What is ABEO's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$29.1M+7,176%
Avg 2 year Forecast
$116.1M+28,919%
Avg 3 year Forecast
$196.0M+48,893%
ABEO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABEO earnings growth forecast

How is ABEO forecast to perform vs Biotechnology companies and vs the US market?

Company
-14.58%
Industry
5.13%
Market
15.2%
ABEO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ABEO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ABEO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ABEO revenue growth forecast

How is ABEO forecast to perform vs Biotechnology companies and vs the US market?

Company
690.23%
Industry
83.67%
Market
10.8%
ABEO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABEO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABEO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABEO$5.64$18.75+232.45%Strong Buy
LXEO$5.36$15.29+185.19%Strong Buy
IMRX$8.07$13.75+70.38%Strong Buy
KRRO$30.38$91.17+200.09%Strong Buy
ALDX$4.90$9.50+93.88%Strong Buy
View Top Biotech Stocks

Abeona Therapeutics Stock Forecast FAQ

Is Abeona Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ABEO) stock is to Strong Buy ABEO stock.

Out of 4 analysts, 1 (25%) are recommending ABEO as a Strong Buy, 3 (75%) are recommending ABEO as a Buy, 0 (0%) are recommending ABEO as a Hold, 0 (0%) are recommending ABEO as a Sell, and 0 (0%) are recommending ABEO as a Strong Sell.

If you're new to stock investing, here's how to buy Abeona Therapeutics stock.

What is ABEO's earnings growth forecast for 2025-2027?

(NASDAQ: ABEO) Abeona Therapeutics's forecast annual earnings growth rate of -14.58% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.2%.

Abeona Therapeutics's earnings in 2025 is $57,242,000.On average, 3 Wall Street analysts forecast ABEO's earnings for 2025 to be $66,492,882, with the lowest ABEO earnings forecast at $50,765,754, and the highest ABEO earnings forecast at $76,405,023. On average, 5 Wall Street analysts forecast ABEO's earnings for 2026 to be $6,666,210, with the lowest ABEO earnings forecast at -$24,100,913, and the highest ABEO earnings forecast at $44,612,329.

In 2027, ABEO is forecast to generate $59,483,105 in earnings, with the lowest earnings forecast at $24,613,699 and the highest earnings forecast at $110,248,859.

What is ABEO's revenue growth forecast for 2025-2027?

(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 690.23% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Abeona Therapeutics's revenue in 2025 is $400,000.On average, 5 Wall Street analysts forecast ABEO's revenue for 2025 to be $1,492,410,599, with the lowest ABEO revenue forecast at $1,096,847,949, and the highest ABEO revenue forecast at $1,695,781,285. On average, 5 Wall Street analysts forecast ABEO's revenue for 2026 to be $5,952,207,693, with the lowest ABEO revenue forecast at $5,036,065,315, and the highest ABEO revenue forecast at $6,684,157,559.

In 2027, ABEO is forecast to generate $10,049,157,845 in revenue, with the lowest revenue forecast at $9,953,164,420 and the highest revenue forecast at $10,255,707,800.

What is ABEO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ABEO) forecast ROA is 23.12%, which is lower than the forecast US Biotechnology industry average of 47.48%.

What is ABEO's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ABEO price target, the average ABEO price target is $18.75, with the highest ABEO stock price forecast at $20.00 and the lowest ABEO stock price forecast at $15.00.

On average, Wall Street analysts predict that Abeona Therapeutics's share price could reach $18.75 by Aug 18, 2026. The average Abeona Therapeutics stock price prediction forecasts a potential upside of 232.45% from the current ABEO share price of $5.64.

What is ABEO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ABEO) Abeona Therapeutics's current Earnings Per Share (EPS) is $1.06. On average, analysts forecast that ABEO's EPS will be $1.30 for 2025, with the lowest EPS forecast at $0.99, and the highest EPS forecast at $1.49. On average, analysts forecast that ABEO's EPS will be $0.13 for 2026, with the lowest EPS forecast at -$0.47, and the highest EPS forecast at $0.87. In 2027, ABEO's EPS is forecast to hit $1.16 (min: $0.48, max: $2.15).

What is ABEO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ABEO) forecast ROE is 34.8%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.